Zacks Investment Research upgraded shares of Savara (NASDAQ:SVRA) from a hold rating to a buy rating in a research report report published on Thursday morning, Zacks.com reports. They currently have $12.00 target price on the stock.

According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “

Other equities analysts also recently issued research reports about the company. LADENBURG THALM/SH SH reaffirmed a buy rating and issued a $21.00 price objective on shares of Savara in a research report on Monday, April 1st. Canaccord Genuity set a $22.00 price objective on Savara and gave the company a buy rating in a research report on Monday, March 25th. BidaskClub raised Savara from a buy rating to a strong-buy rating in a research report on Saturday, May 4th. Roth Capital set a $10.00 price objective on Savara and gave the company a hold rating in a research report on Tuesday, May 14th. Finally, ValuEngine raised Savara from a sell rating to a hold rating in a research report on Monday, April 1st. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Savara presently has an average rating of Buy and an average price target of $21.17.

NASDAQ SVRA opened at $11.48 on Thursday. The company has a market cap of $411.33 million, a PE ratio of -8.90 and a beta of 1.07. The company has a debt-to-equity ratio of 0.24, a quick ratio of 15.63 and a current ratio of 12.05. Savara has a fifty-two week low of $6.21 and a fifty-two week high of $14.06.

Savara (NASDAQ:SVRA) last released its earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. On average, equities analysts expect that Savara will post -1.54 earnings per share for the current year.

In other Savara news, CFO David L. Lowrance sold 7,500 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $9.02, for a total value of $67,650.00. Following the completion of the sale, the chief financial officer now directly owns 2,446 shares in the company, valued at approximately $22,062.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jaakko Taneli Jouhikainen sold 7,815 shares of the company’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $9.00, for a total value of $70,335.00. Following the completion of the sale, the chief operating officer now owns 184,754 shares of the company’s stock, valued at $1,662,786. The disclosure for this sale can be found here. Insiders sold a total of 75,261 shares of company stock worth $744,174 in the last ninety days. 6.50% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of SVRA. FMR LLC purchased a new stake in shares of Savara in the 4th quarter worth $2,830,000. Vanguard Group Inc lifted its holdings in shares of Savara by 23.6% in the 3rd quarter. Vanguard Group Inc now owns 1,246,240 shares of the company’s stock worth $13,908,000 after buying an additional 238,358 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Savara by 23.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,246,240 shares of the company’s stock worth $13,908,000 after buying an additional 238,358 shares during the period. BlackRock Inc. lifted its holdings in shares of Savara by 8.2% in the 3rd quarter. BlackRock Inc. now owns 2,170,294 shares of the company’s stock worth $24,220,000 after buying an additional 164,056 shares during the period. Finally, Morgan Stanley lifted its holdings in shares of Savara by 224.1% in the 3rd quarter. Morgan Stanley now owns 205,560 shares of the company’s stock worth $2,294,000 after buying an additional 142,140 shares during the period. Institutional investors and hedge funds own 47.99% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Savara (SVRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.